New Medical is a supplier of medical consumables, device and patient monitoring accessors.
“Our entry into these markets is a response to growing awareness and clinical demand,” Scott Hensley, VP of sales and business development at ivWatch, said in a press release. “We are now poised to meet the ongoing customer requests for our technology as they seek cutting-edge solutions to address the global problem of patient harm caused by peripheral IV infiltration.”
ivWatch recently received CE Mark approval for its ivWatch Model 400. Once it receives regulatory approval in Australia and New Zealand, the ivWatch Model 400 system will be available for the distributor to sell to clinicians for continuous monitoring.
“Australia is home to vascular access leaders who are undertaking significant scientific research focused on combating IV therapy complications internationally,” Paul Williams, director of New Medical, said. “We’re excited to put our technical team in place to serve the needs of our customers. Our progressive healthcare market is equipped to make reliable early detection and notifications of this common IV complication a part of their efforts toward improving patient safety and outcomes.”